Cargando…
Circulating Tumor Cells in Melanoma Patients
Circulating tumor cells (CTCs) are of recognized importance for diagnosis and prognosis of cancer patients. With melanoma, most studies do not show any clear relationship between CTC levels and stage of disease. Here, CTCs were enriched (∼400X) from blood of melanoma patients using a simple centrifu...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400630/ https://www.ncbi.nlm.nih.gov/pubmed/22829910 http://dx.doi.org/10.1371/journal.pone.0041052 |
_version_ | 1782238515171426304 |
---|---|
author | Clawson, Gary A. Kimchi, Eric Patrick, Susan D. Xin, Ping Harouaka, Ramdane Zheng, Siyang Berg, Arthur Schell, Todd Staveley-O’Carroll, Kevin F. Neves, Rogerio I. Mosca, Paul J. Thiboutot, Diane |
author_facet | Clawson, Gary A. Kimchi, Eric Patrick, Susan D. Xin, Ping Harouaka, Ramdane Zheng, Siyang Berg, Arthur Schell, Todd Staveley-O’Carroll, Kevin F. Neves, Rogerio I. Mosca, Paul J. Thiboutot, Diane |
author_sort | Clawson, Gary A. |
collection | PubMed |
description | Circulating tumor cells (CTCs) are of recognized importance for diagnosis and prognosis of cancer patients. With melanoma, most studies do not show any clear relationship between CTC levels and stage of disease. Here, CTCs were enriched (∼400X) from blood of melanoma patients using a simple centrifugation device (OncoQuick), and 4 melanocyte target RNAs (TYR, MLANA, MITF, and MIF) were quantified using QPCR. Approximately one-third of melanoma patients had elevated MIF and MLANA transcripts (p<0.0001 and p<0.001, respectively) compared with healthy controls. In contrast, healthy controls had uniformly higher levels of TYR and MITF than melanoma patients (p<0.0001). There was a marked shift of leukocytes into the CTC-enriched fractions (a 430% increase in RNA recovery, p<0.001), and no relationship between CTC levels and stage of disease was found. CTCs were captured on microfabricated filters and cultured. Captured melanoma CTCs were large cells, and consisted of 2 subpopulations, based on immunoreactivity. One subpopulation (∼50%) stained for both pan-cytokeratin (KRT) markers and the common leukocyte marker CD-45, whereas the second subpopulation stained for only KRT. Since similar cells are described in many cancers, we also examined blood from colorectal and pancreatic cancer patients. We observed analogous results, with most captured CTCs staining for both CD-45/KRT markers (and for the monocyte differentiation marker CD-14). Our results suggest that immature melanocyte-related cells (expressing TYR and MITF RNA) may circulate in healthy controls, although they are not readily detectable without considerable enrichment. Further, as early-stage melanomas develop, immature melanocyte migration into the blood is somehow curtailed, whereas a significant proportion of patients develop elevated CTC levels (based on MIF and MLANA RNAs). The nature of the captured CTCs is consistent with literature describing leukocyte/macrophage-tumor cell fusion hybrids, and their role in metastatic progression. |
format | Online Article Text |
id | pubmed-3400630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34006302012-07-24 Circulating Tumor Cells in Melanoma Patients Clawson, Gary A. Kimchi, Eric Patrick, Susan D. Xin, Ping Harouaka, Ramdane Zheng, Siyang Berg, Arthur Schell, Todd Staveley-O’Carroll, Kevin F. Neves, Rogerio I. Mosca, Paul J. Thiboutot, Diane PLoS One Research Article Circulating tumor cells (CTCs) are of recognized importance for diagnosis and prognosis of cancer patients. With melanoma, most studies do not show any clear relationship between CTC levels and stage of disease. Here, CTCs were enriched (∼400X) from blood of melanoma patients using a simple centrifugation device (OncoQuick), and 4 melanocyte target RNAs (TYR, MLANA, MITF, and MIF) were quantified using QPCR. Approximately one-third of melanoma patients had elevated MIF and MLANA transcripts (p<0.0001 and p<0.001, respectively) compared with healthy controls. In contrast, healthy controls had uniformly higher levels of TYR and MITF than melanoma patients (p<0.0001). There was a marked shift of leukocytes into the CTC-enriched fractions (a 430% increase in RNA recovery, p<0.001), and no relationship between CTC levels and stage of disease was found. CTCs were captured on microfabricated filters and cultured. Captured melanoma CTCs were large cells, and consisted of 2 subpopulations, based on immunoreactivity. One subpopulation (∼50%) stained for both pan-cytokeratin (KRT) markers and the common leukocyte marker CD-45, whereas the second subpopulation stained for only KRT. Since similar cells are described in many cancers, we also examined blood from colorectal and pancreatic cancer patients. We observed analogous results, with most captured CTCs staining for both CD-45/KRT markers (and for the monocyte differentiation marker CD-14). Our results suggest that immature melanocyte-related cells (expressing TYR and MITF RNA) may circulate in healthy controls, although they are not readily detectable without considerable enrichment. Further, as early-stage melanomas develop, immature melanocyte migration into the blood is somehow curtailed, whereas a significant proportion of patients develop elevated CTC levels (based on MIF and MLANA RNAs). The nature of the captured CTCs is consistent with literature describing leukocyte/macrophage-tumor cell fusion hybrids, and their role in metastatic progression. Public Library of Science 2012-07-19 /pmc/articles/PMC3400630/ /pubmed/22829910 http://dx.doi.org/10.1371/journal.pone.0041052 Text en Clawson et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Clawson, Gary A. Kimchi, Eric Patrick, Susan D. Xin, Ping Harouaka, Ramdane Zheng, Siyang Berg, Arthur Schell, Todd Staveley-O’Carroll, Kevin F. Neves, Rogerio I. Mosca, Paul J. Thiboutot, Diane Circulating Tumor Cells in Melanoma Patients |
title | Circulating Tumor Cells in Melanoma Patients |
title_full | Circulating Tumor Cells in Melanoma Patients |
title_fullStr | Circulating Tumor Cells in Melanoma Patients |
title_full_unstemmed | Circulating Tumor Cells in Melanoma Patients |
title_short | Circulating Tumor Cells in Melanoma Patients |
title_sort | circulating tumor cells in melanoma patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400630/ https://www.ncbi.nlm.nih.gov/pubmed/22829910 http://dx.doi.org/10.1371/journal.pone.0041052 |
work_keys_str_mv | AT clawsongarya circulatingtumorcellsinmelanomapatients AT kimchieric circulatingtumorcellsinmelanomapatients AT patricksusand circulatingtumorcellsinmelanomapatients AT xinping circulatingtumorcellsinmelanomapatients AT harouakaramdane circulatingtumorcellsinmelanomapatients AT zhengsiyang circulatingtumorcellsinmelanomapatients AT bergarthur circulatingtumorcellsinmelanomapatients AT schelltodd circulatingtumorcellsinmelanomapatients AT staveleyocarrollkevinf circulatingtumorcellsinmelanomapatients AT nevesrogerioi circulatingtumorcellsinmelanomapatients AT moscapaulj circulatingtumorcellsinmelanomapatients AT thiboutotdiane circulatingtumorcellsinmelanomapatients |